SCHEMBL25327145

SCHEMBL25327145

C[C@@H]1CN[C@@H](c2ccc(F)cc2)CN1C(=O)C1(C(F)(F)F)CC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 3/20 0.34
TACR3 P29371 4/20 0.34
PSEN1 P49768 3/20 0.33
PSEN2 P49810 3/20 0.33
APH1B Q8WW43 3/20 0.33
NCSTN Q92542 3/20 0.33
APH1A Q96BI3 3/20 0.33
PSENEN Q9NZ42 3/20 0.33
IDO1 P14902 1/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM1A O60341 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
LMNA P02545 1/20 0.31
KDM4E B2RXH2 1/20 0.31
GAA P10253 1/20 0.31
RECQL P46063 1/20 0.31
HRH3 Q9Y5N1 2/20 0.31
DGAT1 O75907 1/20 0.31
POLB P06746 1/20 0.30
HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25914192 1.00 RORC (0.34) RORCTACR3PSEN1PSEN2APH1B
SCHEMBL25327071 0.99 RORC (0.34) RORCTACR3PSEN1PSEN2APH1B
SCHEMBL25329140 0.91 CYP3A4 (0.33) ALDH1A1KDM1ALMNAPOLB
SCHEMBL25327381 0.91 CYP3A4 (0.33) ALDH1A1KDM1ALMNAPOLB
SCHEMBL25327222 0.90 PSEN1 (0.37) TACR3PSEN1PSEN2APH1BNCSTN
SCHEMBL25327423 0.90 PSEN1 (0.37) TACR3PSEN1PSEN2APH1BNCSTN
SCHEMBL25325404 0.89 RIPK1 (0.36) ALDH1A1KDM1APOLB
SCHEMBL25327793 0.88 PSEN1 (0.34) TACR3PSEN1PSEN2APH1BNCSTN
SCHEMBL30523066 0.88 PSEN1 (0.34) TACR3PSEN1PSEN2APH1BNCSTN
SCHEMBL25326007 0.85 PSEN1 (0.36) RORCTACR3PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282749-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-09-11 US disclosed
EP-4469445-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146991-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146991-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282749-A1 COMPOUNDS AND METHODS OF USE CYP1B1, CYP2C19, UGT1A1 RORC 641/4885TACR3 2820/4885PSEN1 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.